Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Top 3 FDA Approvals of 2013

Bad news: The 27 new drugs approved this year is a far cry from 2012's banner year for approvals, in which the Food and Drug Administration signed off on 39 drugs.

Good news: While the quantity might not have been there this year, we've still seen some high-quality drugs with blockbuster potential approved.

While there were many worthy candidates, here are my top three drug approvals from 2013.

Source: Biogen Idec.

Pop a pill
Biogen Idec's (NASDAQ: BIIB  ) Tecfidera was the third oral multiple sclerosis drug to hit the market, but it's been by far the most popular. Within just six months of entering the market, Tecfidera prescriptions surpassed Novartis' Gilenya, which was approved in 2010, and Sanofi's Aubagio, which had a six-month head start. With third-quarter sales of $286 million, Tecfidera is already on pace to reach the illustrious $1 billion blockbuster status.

Tecfidera succeeded where Sanofi and Novartis couldn't mainly because of its strong safety profile. Beating Teva Pharmaceutical's injecteable Copaxone in a head-to-head trial certainly helped, but being just as good as Copaxone would have been enough since Tecfidera is taken orally.

Source: Isis Pharmaceuticals.

Losing the battle, but winning the war
Isis Pharmaceuticals' (NASDAQ: IONS  ) Kynamro probably isn't going to reach blockbuster status anytime soon, if ever. The drug treats a rare disease that causes patients to have dangerously high cholesterol levels. And it appears Aegerion Pharmaceuticals' Juxtapid, which was approved in late 2012, will take most of the market.

But the approval makes the top three for 2013 because Kynamro is the first second-generation RNA antisense drug to be approved. Rather than acting on the protein level to inhibit targets, RNA antisense drugs act upstream of protein synthesis, promoting RNA degradation, which lowers the expression of the protein.

Isis had to overcome many challenges to develop the second-generation product -- Vitravene, the first RNA antisense drug, was approved in 1998 -- and now the platform can be applied to any target that needs to be inhibited to treat a disease. The flexibility is obvious in the 25+ drugs that Isis has in its pipeline.

Source: Gilead Sciences.

A joint honor goes to hepatitis C drugs from Johnson & Johnson (NYSE: JNJ  ) and Gilead Sciences (NASDAQ: GILD  ) . Gilead's Sovaldi is arguably the better drug, but Johnson & Johnson gets honorable mention for Olysio.

Neither drug is going to reach its full potential on its own. For both drugs, patients infected with genotype 1 hepatitis C virus need to take pegylated interferon, which must be injected and has nasty side effects.

Ultimately, a cocktail of drugs will be the standard of care. There's evidence that Sovaldi and Olysio might work together without interferon, but the combination hasn't been endorsed by the FDA. The first FDA approvals will come from combinations being tested in phase 3 trials; Gilead has a cocktail that includes Sovaldi and AbbVie has a cocktail of its own, leaving Johnson & Johnson out in the cold.

Start investing in 2014
Millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2780182, ~/Articles/ArticleHandler.aspx, 9/25/2016 12:17:49 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
BIIB $312.58 Down -2.23 -0.71%
Biogen CAPS Rating: *****
GILD $81.37 Down -0.15 -0.18%
Gilead Sciences CAPS Rating: *****
IONS $35.12 Up +0.10 +0.29%
Ionis Pharmaceutic… CAPS Rating: *****
JNJ $118.81 Down -0.65 -0.54%
Johnson and Johnso… CAPS Rating: *****
ABBV $64.98 Down -0.10 -0.15%
AbbVie CAPS Rating: ****
AEGR $2.75 Up +0.10 +3.77%
Aegerion Pharmaceu… CAPS Rating: **
NVS $81.48 Down -0.55 -0.67%
Novartis CAPS Rating: ****